Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have fully completed the TRIUMPH, SHEPHERD, or X03-001 studies~* TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures~* Patient must be willing and able to give written informed consent~* Patient must avoid conception during the trial~Exclusion Criteria:~* Patients who have terminated early from the SHEPHERD or X03-001 studies~* Patients who have terminated early from the TRIUMPH study due to an adverse event~* Female who is pregnant, breast feeding, or intending to conceive during the course of the study~* Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): 600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).